Aktuellt
SENASTE
Redeye briefly comments on Isofol’s Q3 2021 report, which came without any surprises. We view top-line data from the company’s pivotal AGENT trial as the key catalyst going forward, scheduled for release in H1 2022. AGENT is an event-driven study, and we view the trial reaching 300 PFS events as the next catalyst for Isofol. Our model suggests substantial upside.
LÄS MER
